{"id":755882,"date":"2023-05-08T08:14:25","date_gmt":"2023-05-08T12:14:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/"},"modified":"2023-05-08T08:14:25","modified_gmt":"2023-05-08T12:14:25","slug":"enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/","title":{"rendered":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy"},"content":{"rendered":"
\n

\n Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) — <\/strong>Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, \u201cCombination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.\u201d The patent provides added intellectual property protection in Europe into at least 2037, with claims covering the use of for Allocetra\u2122 for the prevention or amelioration of cytokine storms in cancer patients receiving CAR T-Cell therapy.<\/p>\n

\n ABOUT ALLOCETRA\u2122<\/strong>
\n
Allocetra\u2122 is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra\u2122 has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.<\/p>\n

\n ABOUT <\/strong>
\n ENLIVEX<\/strong>
\n
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra\u2122, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http:\/\/www.enlivex.com.<\/a><\/p>\n

\n Safe Harbor Statement:\u00a0 This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<\/em>
\n
\n TM<\/em>
\n <\/sup>
\n \u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\u00a0 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect\u00a0<\/em>
\n Enlivex\u2019s<\/em>
\n \u00a0business and prospects, including the risks that\u00a0<\/em>
\n Enlivex<\/em>
\n \u00a0may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<\/em>
\n
\n TM<\/em>
\n <\/sup>
\n \u00a0product line could also be affected by\u00a0<\/em>
\n a number of<\/em>
\n \u00a0other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.\u00a0 In addition to the risk factors described above, investors should <\/em>
\n consider the economic, competitive, governmental,\u00a0<\/em>
\n technological<\/em>
\n \u00a0and other factors discussed in\u00a0<\/em>
\n Enlivex\u2019s<\/em>
\n \u00a0filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.\u00a0 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/em>\n <\/p>\n

\n ENLIVEX CONTACT<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Shachar Shlosberger, CFO\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Enlivex Therapeutics, Ltd.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
shachar@enlivexpharm.com<\/a><\/p>\n

\n INVESTOR RELATIONS CONTACT<\/strong>
\n
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com<\/a><\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, \u201cCombination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.\u201d The patent provides added intellectual property protection in Europe into at least 2037, with claims covering the use of for Allocetra\u2122 for the prevention or amelioration of cytokine storms in cancer patients receiving CAR T-Cell therapy. ABOUT ALLOCETRA\u2122 Allocetra\u2122 is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to … <\/p>\n

Continue reading “Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-755882","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, \u201cCombination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.\u201d The patent provides added intellectual property protection in Europe into at least 2037, with claims covering the use of for Allocetra\u2122 for the prevention or amelioration of cytokine storms in cancer patients receiving CAR T-Cell therapy. ABOUT ALLOCETRA\u2122 Allocetra\u2122 is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to … Continue reading "Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-08T12:14:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy\",\"datePublished\":\"2023-05-08T12:14:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/\"},\"wordCount\":638,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/\",\"name\":\"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==\",\"datePublished\":\"2023-05-08T12:14:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk","og_description":"Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered 3865189, entitled, \u201cCombination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.\u201d The patent provides added intellectual property protection in Europe into at least 2037, with claims covering the use of for Allocetra\u2122 for the prevention or amelioration of cytokine storms in cancer patients receiving CAR T-Cell therapy. ABOUT ALLOCETRA\u2122 Allocetra\u2122 is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to … Continue reading \"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-08T12:14:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy","datePublished":"2023-05-08T12:14:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/"},"wordCount":638,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/","name":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==","datePublished":"2023-05-08T12:14:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgzMzI1MSM1NTc4NTQ2IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-european-patent-covering-the-use-of-allocetra-to-prevent-cytokine-release-syndrome-crs-resulting-from-car-t-cell-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex Announces Issuance of European Patent Covering the Use of Allocetra\u2122 to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=755882"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/755882\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=755882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=755882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=755882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}